Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw.

Abstract

We describe a case of a 64-year-old female diagnosed with multiple myeloma in 2001. She was treated with pamidronate and subsequently zolodronic acid before developing spontaneous bisphosphonate related osteonecrosis (BRONJ) of the left maxilla in December 2008. Over the next two years the BRONJ was treated conservatively but gradually became more symptomatic. About three years after her last dose of zolodronic acid with her symptoms increasing, she underwent radical surgical excision of all diseased bone and flap reconstruction. The patient is now six months postoperative and symptom free.

• Authors: I Hewson, D Syme, F Bruscino-Raiola
• Journal: Australian dental journal (Aust Dent J) Vol. 57 Issue 2 Pg. 227-30 (Jun 2012) ISSN: 1834-7819 [Electronic] Australia
• PMID: 22624766 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2012 Australian Dental Association.

Chemical References

• Bone Density Conservation Agents
• Collagen Type I
• Diphosphonates
• Imidazoles
• Peptides
• collagen type I trimeric cross-linked peptide
• Zoledronic Acid
• Pamidronate

Topics

• Bisphosphonate-Associated Osteonecrosis of the Jaw (surgery)
• Bone Density Conservation Agents (adverse effects)
• Collagen Type I (blood)
• Diphosphonates (adverse effects)
• Female
• Humans
• Imidazoles (adverse effects)
• Maxillary Diseases (surgery)
• Maxillary Osteotomy (methods)
• Middle Aged
• Multiple Myeloma (drug therapy)
• Pamidronate
• Peptides (blood)
• Surgical Flaps
• Tooth Extraction (adverse effects)
• Zoledronic Acid